Preparation of RGD-modified Long Circulating Liposome Loading Matrine, and Its in Vitro Anti-cancer Effects

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2010 Jul 3

PMID 20596360

Citations 14

Authors

Xiao-Yan Liu

Li-Ming Ruan

Wei-Wei Mao

Jin-Qiang Wang

You-Qing Shen

Mei-hua Sui

Affiliations

Soon will be listed here.

Abstract

Aim: To prepare RGD-modified long circulating liposome (LCL) loading matrine (RGD-M-LCL) to improve the tumor-targeting and efficacy of matrine.

Methods: LCL which was prepared with HSPC, cholesterol, DSPE-PEG2000 and DSPE-PEG-MAL was modified with an RGD motif confirmed by high performance liquid chromatography (HPLC). The encapsulation efficiency of RGD-M-LCL was also detected by HPLC. MTT assay was used to examine the effects of RGD-M-LCL on the proliferation of Bcap-37, HT-29 and A375 cells. The percentage of apoptotic cells and morphological changes in Bcap-37 cells treated with RGD-M-LCL were detected by Annexin-V-FITC/PI affinity assay and observed under light microscope, respectively.

Results: Spherical or oval single-chamber particles of uniform sizes with little agglutination or adhesion were observed under transmission electronic microscope. The RGD motif was successfully coupled to the DSPE-PEG-MAL on liposomes, as confirmed by HPLC. An encapsulation efficiency of 83.13% was obtained when the drug-lipid molar ratio was 0.1, and the encapsulation efficiency was negatively related to the drug-lipid ratio in the range of 0.1-0.4, and to the duration of storage. We found that, compared with free matrine, RGD-M-LCL had much stronger in vitro activity, leading to anti-proliferative and pro-apoptotic effects against cancer cells (P<0.01).

Conclusion: RGD-M-LCL, a novel delivery system for anti-cancer drugs, was successfully prepared, and we demonstrated that the use of this material could augment the effects of matrine on cancer cells in vitro.

Citing Articles

Curcumin-Loaded Long-Circulation Liposomes Ameliorate Insulin Resistance in Type 2 Diabetic Mice.

Li K, Yuan H, Zhang J, Peng X, Zhuang W, Huang W Int J Nanomedicine. 2024; 19:12099-12110.

PMID: 39583326 PMC: 11585265. DOI: 10.2147/IJN.S487519.

Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer.

Zhang J, Ali K, Wang J Int J Nanomedicine. 2024; 19:6693-6715.

PMID: 38979534 PMC: 11229238. DOI: 10.2147/IJN.S466490.

Long-Circulating Lipid Nanospheres Loaded with Flurbiprofen Axetil for Targeted Rheumatoid Arthritis Treatment.

Chen Z, Liu Z, Wang S, Cheng C, Sun X, Liu Z Int J Nanomedicine. 2023; 18:5159-5181.

PMID: 37705869 PMC: 10497098. DOI: 10.2147/IJN.S419502.

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products.

Cheng X, Yan H, Pang S, Ya M, Qiu F, Qin P Front Chem. 2022; 10:963004.

PMID: 36003616 PMC: 9393238. DOI: 10.3389/fchem.2022.963004.

Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer.

Gaurav I, Wang X, Thakur A, Iyaswamy A, Thakur S, Chen X Pharmaceutics. 2021; 13(9).

PMID: 34575511 PMC: 8471603. DOI: 10.3390/pharmaceutics13091433.

References

Qiu L, Jing N, Jin Y . Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. Int J Pharm. 2008; 361(1-2):56-63. DOI: 10.1016/j.ijpharm.2008.05.010. View

Maeda H, Bharate G, Daruwalla J . Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2008; 71(3):409-19. DOI: 10.1016/j.ejpb.2008.11.010. View

Xiong X, Huang Y, Lu W, Zhang X, Zhang H, Nagai T . Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005; 107(2):262-75. DOI: 10.1016/j.jconrel.2005.03.030. View

Rhim J, Tosato G . Targeting the tumor vasculature to improve the efficacy of oncolytic virus therapy. J Natl Cancer Inst. 2007; 99(23):1739-41. DOI: 10.1093/jnci/djm234. View

Liu S . Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm. 2006; 3(5):472-87. DOI: 10.1021/mp060049x. View

Jiang H, Hou C, Zhang S, Xie H, Zhou W, Jin Q . Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol. 2007; 559(2-3):98-108. DOI: 10.1016/j.ejphar.2006.12.017. View

Haran G, Cohen R, Bar L, Barenholz Y . Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993; 1151(2):201-15. DOI: 10.1016/0005-2736(93)90105-9. View

Mai J, Song S, Rui M, Liu D, Ding Q, Peng J . A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J Control Release. 2009; 139(3):174-81. DOI: 10.1016/j.jconrel.2009.06.024. View

Immordino M, Dosio F, Cattel L . Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2007; 1(3):297-315. PMC: 2426795. View

10.

Zhang L, Jiang J, Tam J, Zhang Y, Liu X, Xu X . Effects of Matrine on proliferation and differentiation in K-562 cells. Leuk Res. 2001; 25(9):793-800. DOI: 10.1016/s0145-2126(00)00145-4. View

11.

Ma L, Wen S, Zhan Y, He Y, Liu X, Jiang J . Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med. 2008; 74(3):245-51. DOI: 10.1055/s-2008-1034304. View

12.

Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, Kim J . A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res. 2009; 69(16):6531-8. DOI: 10.1158/0008-5472.CAN-08-3945. View

13.

Ellis L . A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am Surg. 2003; 69(1):3-10. View

14.

Chakrabarti S, Williams T, Dillman R, Siahaan T . Solution stability of linear vs. cyclic RGD peptides. J Pept Res. 1999; 53(5):530-41. DOI: 10.1034/j.1399-3011.1999.00052.x. View

15.

Reddy P, Ganesh S, Yu D . Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin Cancer Res. 2006; 12(9):2869-78. DOI: 10.1158/1078-0432.CCR-05-2397. View

16.

Gabizon A, Shmeeda H, Zalipsky S . Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2006; 16(3):175-83. DOI: 10.1080/08982100600848769. View

17.

Okroj M, Dobrzanska-Paprocka Z, Rolka K, Bigda J . In vitro and in vivo analyses of the biological activity of RGD peptides towards Ab Bomirski melanoma. Cell Mol Biol Lett. 2003; 8(4):873-84. View

18.

Dijkgraaf I, Kruijtzer J, Frielink C, Soede A, Hilbers H, Oyen W . Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists. Nucl Med Biol. 2006; 33(8):953-61. DOI: 10.1016/j.nucmedbio.2006.08.008. View

19.

Schiffelers R, Ansari A, Xu J, Zhou Q, Tang Q, Storm G . Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004; 32(19):e149. PMC: 528817. DOI: 10.1093/nar/gnh140. View

20.

Lin H, Lansing L, Merillon J, Davis F, Tang H, Shih A . Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J. 2006; 20(10):1742-4. DOI: 10.1096/fj.06-5743fje. View